Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDCara Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$2.40 | -$2.40 | -$2.40 |
| Q2 2025 | 1 | -$2.52 | -$2.52 | -$2.52 |
| Q3 2025 | 1 | -$2.76 | -$2.76 | -$2.76 |
| Q4 2025 | 1 | -$2.40 | -$2.40 | -$2.40 |
Cara Therapeutics, Inc. Earnings Date And Information
Cara Therapeutics, Inc. last posted its earnings results on Thursday, November 14th, 2024. The company reported $-1.8 earnings per share for the quarter, topping analysts' consensus estimates of $-3 by $1.2. The company had revenue of 2.56 M for the quarter and had revenue of 7.14 M for the year. Cara Therapeutics, Inc. has generated $0 earnings per share over the last year ($-0.0155 diluted earnings per share) and currently has a price-to-earnings ratio of -2.93. Cara Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 3rd, 2025 based on prior year's report dates.
Cara Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | -$3.00 | -$0.23 | 2.77 | $2.02 M | $2.56 M |
| 08/14/2024 | Q2 2024 | -$3.48 | -$0.37 | 3.11 | $1.18 M | $991,000 |
| 05/13/2024 | Q1 2024 | -$4.56 | -$0.56 | 4 | N/A | $2.14 M |
| 03/06/2024 | Q4 2023 | N/A | -$0.59 | N/A | N/A | $3.00 M |
| 11/13/2023 | Q3 2023 | -$6.36 | -$0.52 | 5.84 | $9.95 M | $4.87 M |
| 08/07/2023 | Q2 2023 | -$6.72 | -$0.58 | 6.14 | $6.50 M | $6.93 M |
| 05/15/2023 | Q1 2023 | -$6.36 | -$0.48 | 5.88 | N/A | $6.17 M |
| 03/06/2023 | Q4 2022 | -$3.96 | -$0.55 | 3.41 | N/A | $3.26 M |
| 11/07/2022 | Q3 2022 | -$5.04 | -$0.42 | 4.62 | $8.84 M | $10.81 M |
| 08/08/2022 | Q2 2022 | -$3.36 | -$0.07 | 3.29 | $21.11 M | $23.00 M |
| 05/09/2022 | Q1 2022 | -$6.72 | -$0.52 | 6.2 | N/A | $4.79 M |
| 03/01/2022 | Q4 2021 | -$6.00 | -$0.63 | 5.37 | N/A | $821,000 |
| 11/08/2021 | Q3 2021 | -$4.32 | -$0.02 | 4.3 | $15.59 M | $20.27 M |
| 08/09/2021 | Q2 2021 | -$6.60 | -$0.61 | 5.99 | $2.59 M | $0 |
| 05/10/2021 | Q1 2021 | -$7.44 | -$0.47 | 6.97 | N/A | $1.94 M |
| 02/25/2021 | Q4 2020 | -$6.36 | $1.68 | 8.04 | N/A | $112.09 M |
| 11/09/2020 | Q3 2020 | -$8.16 | -$0.35 | 7.81 | $4.73 M | $9.27 M |
| 08/10/2020 | Q2 2020 | -$8.16 | -$0.54 | 7.62 | $5.01 M | $5.63 M |
| 05/11/2020 | Q1 2020 | -$7.56 | -$0.62 | 6.94 | N/A | $8.09 M |
| 02/27/2020 | Q4 2019 | -$7.44 | -$0.61 | 6.83 | N/A | $4.51 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Cara Therapeutics, Inc. Earnings: FAQ's
Cara Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 3rd, 2025 based offlast year's report dates.
In the previous quarter, Cara Therapeutics, Inc. (:CARA) reported $-1.8 earnings per share (EPS) to beat the analysts' consensus estimate of $-3 by $1.2.
The conference call for Cara Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Cara Therapeutics, Inc.'s latest earnings report can be read online.
Cara Therapeutics, Inc. (:CARA) has a recorded annual revenue of $7.14 M.
Cara Therapeutics, Inc. (:CARA) has a recorded net income of $-70,867,000.Cara Therapeutics, Inc. has generated $-0.0155 earnings per share over the last four quarters.
Cara Therapeutics, Inc. (:CARA) has a price-to-earnings ratio of -2.93 and price/earnings-to-growth ratio is -0.21.